Journal articles on the topic 'Taxane-based therapy'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Taxane-based therapy.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Sparano, Joseph A., and Lakshmi Rajdev. "Taxane-Based Therapy for Breast Cancer: Combination or Sequential Therapy?" Cancer Investigation 18, no. 5 (January 2000): 498–500. http://dx.doi.org/10.3109/07357900009032823.
Full textDwipoyono, Bambang, Septyana Choirunisa, Mardiati Nadjib, and Amal C. Sjaaf. "COST ANALYSIS OF TAXANE-BASED AND CISPLATIN-BASED CHEMOTHERAPY REGIMENS FOR EPITHELIAL OVARIAN CANCER IN DHARMAIS NATIONAL CANCER HOSPITAL." International Journal of Applied Pharmaceutics 9 (October 30, 2017): 172. http://dx.doi.org/10.22159/ijap.2017.v9s1.82_89.
Full textPiccart-Gebhart, M. J., and P. L. Bedard. "Who benefits from taxanes?" Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e11503-e11503. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e11503.
Full text&NA;. "Abdominal pain may signal colitis in taxane-based therapy." Inpharma Weekly &NA;, no. 1461 (October 2004): 17. http://dx.doi.org/10.2165/00128413-200414610-00040.
Full text&NA;. "Abdominal pain may signal colitis in taxane-based therapy." Reactions Weekly &NA;, no. 1025 (October 2004): 5. http://dx.doi.org/10.2165/00128415-200410250-00009.
Full textArmstrong, Andrew J., Jun Luo, Monika Anand, Emmanuel S. Antonarakis, David M. Nanus, Paraskevi Giannakakou, Russell Zelig Szmulewitz, et al. "AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY." Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020): 184. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.184.
Full textLaino, Charlene. "Adding Taxane to Anthracycline-Based Therapy Does Not Improve Outcomes." Oncology Times 30, no. 12 (June 2008): 37–39. http://dx.doi.org/10.1097/01.cot.0000326170.34970.c4.
Full textChelala, Elias, Nicolas Arej, Joelle Antoun, Hampig Raphael Kourie, Karen Zaarour, Fady Ghassan Haddad, Fadi Farhat, Fadi El Karak, and Joseph Kattan. "Central Macular Thickness Monitoring after a Taxane-Based Therapy in Visually Asymptomatic Patients." Chemotherapy 62, no. 3 (2017): 199–204. http://dx.doi.org/10.1159/000456653.
Full textHigano, Celestia S., Lauren C. Harshman, Sabina Dizdarevic, John Logue, Timothy Richardson, Saby George, Danny Song, et al. "Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 5542. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5542.
Full textmoloney, carolyn, Sue Sukor, Michael Thomas McCarthy, and Cliona Grant. "A review of head and neck squamous cell carcinoma response to taxane chemotherapy treatment in the pre versus post nivolumab era." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e18504-e18504. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e18504.
Full textAgarwal, Neeraj, Simon Chowdhury, Anders Bjartell, Byung Ha Chung, Andrea Juliana Pereira de Santana Gomes, Robert W. Given, Álvaro Juárez Soto, et al. "Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane)." Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020): 82. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.82.
Full textDeng, Shanshan, Raisa I. Krutilina, Deanna Parke, Hao Chen, Duane D. Miller, Wei Li, and Tiffany Nicole Seagroves. "VERU-111: An Oral Tubulin Inhibitor That Suppresses Taxane-Sensitive and Taxane-Resistant Breast Cancer." Journal of the Endocrine Society 5, Supplement_1 (May 1, 2021): A1035. http://dx.doi.org/10.1210/jendso/bvab048.2118.
Full textAl-Ezzi, Esmail Mutahar, Jamila Jama Almi Riromar, Eitan Amir, Rouhi Fazelzad, and Aaron Richard Hansen. "Cross-trial comparison of taxane versus non-taxane combination chemotherapy regimens for advanced penile cancer (APC): A systematic review." Journal of Clinical Oncology 37, no. 7_suppl (March 1, 2019): 511. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.511.
Full textSonpavde, Guru, Gregory Russell Pond, Giuseppe di Lorenzo, Carlo Buonerba, Antonio Rozzi, Gaetano Lanzetta, Andrea Necchi, et al. "Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC)." Journal of Clinical Oncology 34, no. 2_suppl (January 10, 2016): 386. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.386.
Full textCecchi, Fabiola, Daniel V. T. Catenacci, Yuan Tian, Rosalba Miceli, Filippo Pietrantonio, Alessandro Pellegrinelli, Antonia Martinetti, Maria Di Bartolomeo, and Todd A. Hembrough. "Quantitative proteomic analysis of TUBB3 to identify gastric cancer patients who may benefit from docetaxel: A reevaluation of the ITACA-S trial." Journal of Clinical Oncology 35, no. 4_suppl (February 1, 2017): 59. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.59.
Full textGitlitz, B. J., A. M. Davies, C. P. Belani, A. Argiris, S. S. Ramalingam, P. C. Hoffman, M. Koczwas, S. G. Groshen, and D. R. Gandara. "A phase II study of the halichondrin B analog, E7389, in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane. A California Consortium/University of Pittsburgh/University of Chicago NCI/CTEP sponsored trial." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 8056. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.8056.
Full textVarayathu, Hrishi, Hephzibah Sara Mathew, Vinu Sarathy, Beulah Elsa Thomas, Santosh Elluru Kumar, Nitheesha Reddy, Suhail Sayeed Mufti, et al. "Taxane induced pulmonary toxicity in breast cancer." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e15522-e15522. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e15522.
Full textFreedman, Rachel A., Ines Maria Vaz Duarte Luis, Nancy Lin, Joyce Lii, Eric P. Winer, and Nancy Lynn Keating. "Completion of adjuvant trastuzumab for older patients with early-stage breast cancer (BC)." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 616. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.616.
Full textMaxwell, Cathy. "Quality-of-Life Considerations With Taxane-Based Therapy in Metastatic Breast Cancer." Clinical Journal of Oncology Nursing 17 (January 29, 2013): 35–40. http://dx.doi.org/10.1188/13.cjon.s1.35-40.
Full textAldrich, Jeffrey D., Kanwal Pratap Singh Raghav, Gauri R. Varadhachary, Robert A. Wolff, and Michael J. Overman. "Retrospective analysis of taxane-based therapy in advanced small bowel adenocarcinoma (SBA)." Journal of Clinical Oncology 36, no. 15_suppl (May 20, 2018): e16263-e16263. http://dx.doi.org/10.1200/jco.2018.36.15_suppl.e16263.
Full textBottsford-Miller, Justin, Hyun-Jin Choi, Heather J. Dalton, Rebecca L. Stone, Min Soon Cho, Monika Haemmerle, Alpa M. Nick, et al. "Differential Platelet Levels Affect Response to Taxane-Based Therapy in Ovarian Cancer." Clinical Cancer Research 21, no. 3 (December 3, 2014): 602–10. http://dx.doi.org/10.1158/1078-0432.ccr-14-0870.
Full textOta, Shuji, Takahiko Sakamoto, Ryosuke Ochiai, Terunobu Haruyama, Masashi Ishihara, Maika Natsume, Yoko Fukasawa, et al. "Successful Treatment with Taxane-Based Chemotherapy in Advanced Sebaceous Carcinoma: A Case Report and Literature Review." Case Reports in Oncology 12, no. 1 (January 11, 2019): 47–52. http://dx.doi.org/10.1159/000493850.
Full textYee, Samantha S., and April L. Risinger. "Efficacy of a Covalent Microtubule Stabilizer in Taxane-Resistant Ovarian Cancer Models." Molecules 26, no. 13 (July 3, 2021): 4077. http://dx.doi.org/10.3390/molecules26134077.
Full textHowell, Anthony, and Andrew M. Wardley. "Overview of the impact of conventional systemic therapies on breast cancer." Endocrine-Related Cancer 12, Supplement_1 (July 2005): S9—S16. http://dx.doi.org/10.1677/erc.1.01003.
Full textUeno, N. T., S. Kim, W. F. Symmans, M. A. Detry, L. Pusztai, L. F. Sanchez, H. Ishihara, G. N. Hortobagyi, and S. Noguchi. "Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 586. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.586.
Full textLoRusso, Stephen, Henry Piascik, and Karen Wonders. "Do Taxane Based Chemotherapies Impair Improvements in VO2 in Female Cancer Survivors." Medicine & Science in Sports & Exercise 51, Supplement (June 2019): 244. http://dx.doi.org/10.1249/01.mss.0000561239.26881.f0.
Full textJegerski, Maura, Karen Wonders, and Stephen LoRusso. "Taxane Based Chemotherapies Impact on Balance and VO2 in Female Cancer Survivors." Medicine & Science in Sports & Exercise 51, Supplement (June 2019): 244. http://dx.doi.org/10.1249/01.mss.0000561240.21043.2e.
Full textMcCourt, Carolyn, Sybil Dessie, Ann Marie Bradley, Joanna Schwartz, Laurent Brard, and Don S. Dizon. "Is There a Taxane-Free Interval That Predicts Response to Taxanes as a Later-Line Treatment of Recurrent Ovarian or Primary Peritoneal Cancer?" International Journal of Gynecologic Cancer 19, no. 3 (March 2009): 343–47. http://dx.doi.org/10.1111/igc.0b013e3181a12eb9.
Full textSathianathen, Niranjan J., Yiannis A. Philippou, Gretchen M. Kuntz, Badrinath R. Konety, Shilpa Gupta, Alastair D. Lamb, and Philipp Dahm. "Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer: a Cochrane Review." BJU International 124, no. 3 (March 20, 2019): 370–72. http://dx.doi.org/10.1111/bju.14711.
Full textBurstein, H. J., A. Keshaviah, A. Baron, R. Hart, R. Lambert-Falls, P. K. Marcom, R. Gelman, and E. P. Winer. "Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 650. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.650.
Full textAli, Haythem Y., Zaid Abdel Rahman, and Jawad Sheqwara. "A differential response to cetuximab in patients with recurrent unresectable or metastatic head and neck cancer following immunotherapy (IO) exposure: An institutional experience." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e17500-e17500. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e17500.
Full textFurlanetto, Jenny, and Sibylle Loibl. "Optimal Systemic Treatment for Early Triple-Negative Breast Cancer." Breast Care 15, no. 3 (2020): 217–26. http://dx.doi.org/10.1159/000508759.
Full textRogers, Jane E., and Jaffer A. Ajani. "Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy." Journal of Clinical Oncology 37, no. 30 (October 20, 2019): 2805–6. http://dx.doi.org/10.1200/jco.19.01247.
Full textPiccart-Gebhart, Martine J., Tomasz Burzykowski, Marc Buyse, George Sledge, James Carmichael, Hans-Joachim Lück, John R. Mackey, et al. "Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer." Journal of Clinical Oncology 26, no. 12 (April 20, 2008): 1980–86. http://dx.doi.org/10.1200/jco.2007.10.8399.
Full textSchneider, B. P., M. Wang, V. Stearns, S. Martino, V. E. Jones, E. A. Perez, T. J. Saphner, et al. "Relationship between taxane-induced neuropathy and clinical outcomes after adjuvant chemotherapy." Journal of Clinical Oncology 29, no. 27_suppl (September 20, 2011): 270. http://dx.doi.org/10.1200/jco.2011.29.27_suppl.270.
Full textSeto, Tiffany, Navendu D. Samant, Nina Shah, Aida Shirazi, A. Dimitrios Colevas, and Jed Abraham Katzel. "Treatment patterns for patients with metastatic or recurrent head and neck cancer in a large integrated health-care system." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e18015-e18015. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e18015.
Full textGaron, Edward B., Giorgio Vittorio Scagliotti, Oliver Gautschi, Martin Reck, Michael Thomas, Lara Iglesias Docampo, Haralabos Kalofonos, et al. "Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy." ESMO Open 5, no. 1 (January 2020): e000567. http://dx.doi.org/10.1136/esmoopen-2019-000567.
Full textGarces, Christopher A., and William G. Cance. "Neoadjuvant Chemotherapy of Breast Cancer." American Surgeon 70, no. 7 (July 2004): 565–69. http://dx.doi.org/10.1177/000313480407000701.
Full textChou, Ching-Wen, Yu-Min Huang, Yu-Jia Chang, Chien-Yu Huang, and Chin-Sheng Hung. "Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer." International Journal of Medical Sciences 18, no. 12 (2021): 2521–31. http://dx.doi.org/10.7150/ijms.59177.
Full textAzambuja, E., V. Durbecq, D. D. Rosa, M. Colozza, D. Larsimont, M. Piccart-Gebhart, and F. Cardoso. "HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer." Annals of Oncology 19, no. 2 (February 2008): 223–32. http://dx.doi.org/10.1093/annonc/mdm352.
Full textPillai, Rathi N., Seth A. Brodie, Gabriel L. Sica, You Shaojin, Ge Li, Dana C. Nickleach, Liu Yuan, et al. "CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC." Clinical Cancer Research 19, no. 6 (February 5, 2013): 1603–11. http://dx.doi.org/10.1158/1078-0432.ccr-12-2995.
Full textWeiss, Anna, Sami Bashour, Limin Hsu, Kenneth R. Hess, Alastair Mark Thompson, and Nuhad K. Ibrahim. "Effect of neoadjuvant chemotherapy regimen choice in patients with breast cancer with pathologic complete response." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 570. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.570.
Full textNadler, Eric S., Seongjung Joo, Jenny Black-Shinn, Marley Boyd, Joseph Zhuo, and Diana Romana Chirovsky. "Treatment patterns in recurrent/metastatic head and neck squamous cell carcinoma in the US." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 6033. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.6033.
Full textGandhi, S., G. G. Fletcher, A. Eisen, M. Mates, O. C. Freedman, S. F. Dent, and M. E. Trudeau. "Adjuvant chemotherapy for early female breast cancer: A systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline." Current Oncology 22 (December 18, 2014): 82. http://dx.doi.org/10.3747/co.22.2321.
Full textvan den Ende, Tom, Emil ter Veer, Mélanie Machiels, Rosa Mali, Frank Abe Nijenhuis, Laura de Waal, Marety Laarman, et al. "The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis." Cancers 11, no. 1 (January 11, 2019): 80. http://dx.doi.org/10.3390/cancers11010080.
Full textMarkowska, J., M. Bidziáski, J. Stelmachów, E. Kraszewska, I. Ziółkowska-Seta, R. Madry, A. Timorek, A. Rembiszewska, and J. Kupryjaáczyk. "Profiles of ovarian cancer patients that benefit from taxane-platinum and platinum-based chemotherapy." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 16005. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.16005.
Full textFujisawa, Yasuhiro, Yasuhiro Nakamura, Yasuhiro Kawachi, and Fujio Otsuka. "Comparison between taxane-based chemotherapy with conventional surgery-based therapy for cutaneous angiosarcoma: a single-center experience." Journal of Dermatological Treatment 25, no. 5 (June 6, 2013): 419–23. http://dx.doi.org/10.3109/09546634.2012.754839.
Full textHarris, Carole A., Sallie Pearson, Benjamin Daniels, Preeyaporn Srasuebkul, and Robyn L. Ward. "HER2-positive early breast cancer (HER2EBC): An Australian pattern of care study." Journal of Clinical Oncology 31, no. 31_suppl (November 1, 2013): 101. http://dx.doi.org/10.1200/jco.2013.31.31_suppl.101.
Full textGizzi, Marco, Giulia Baciarello, Aude Flechon, Philippe Beuzeboc, Antoine Angelergues, Guilhem Roubaud, Emmanuelle Bompas, et al. "Previous enzalutamide therapy and response to subsequent taxane therapy in metastatic castration-resistant prostate cancer." Journal of Clinical Oncology 33, no. 7_suppl (March 1, 2015): 227. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.227.
Full textHur, Min Hee, Tae Ho Kang, Ra Joo Im, Se Won Kim, Chan Seok Yoon, Seung Sang Ko, Haekyung Lee, Ji Hyun Lee, and Sung-Soo Kang. "Clinical characteristics and chemotherapy options of triple-negative breast cancer: Role of classical CMF regimen." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 1053. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.1053.
Full text